Comparative Pharmacology
Head-to-head clinical analysis: ISENTRESS versus ISENTRESS HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISENTRESS versus ISENTRESS HD.
ISENTRESS vs ISENTRESS HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of HIV-1 integrase, blocking strand transfer step of retroviral DNA integration into host genome.
Integrase strand transfer inhibitor (INSTI). Inhibits the catalytic activity of HIV-1 integrase, preventing integration of viral DNA into host genome.
400 mg orally twice daily.
600 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 7–12 hours; no significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 12.9 hours in adults, supporting twice-daily dosing. Prolonged in hepatic impairment.
Renal (approximately 51% as unchanged drug via glomerular filtration and active tubular secretion) and fecal (approximately 32% as unchanged drug).
Primarily hepatic metabolism via UGT1A1 with glucuronidation; 51% excreted in feces (mainly as parent drug) and 32% in urine (mostly as metabolites).
Category C
Category C
HIV Integrase Inhibitor
HIV Integrase Inhibitor